ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 245 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,055,400 | -95.1% | 50,643 | -94.3% | 0.00% | -95.3% |
| Q2 2023 | $21,361,628 | +72.1% | 891,926 | +35.2% | 0.06% | +68.4% |
| Q1 2023 | $12,411,906 | -30.1% | 659,506 | -40.9% | 0.04% | -36.7% |
| Q4 2022 | $17,765,128 | +246.2% | 1,115,900 | +461.0% | 0.06% | +150.0% |
| Q1 2021 | $5,132,000 | -42.6% | 198,900 | +19.0% | 0.02% | -45.5% |
| Q4 2020 | $8,933,000 | -62.5% | 167,100 | -71.1% | 0.04% | -63.9% |
| Q3 2020 | $23,851,000 | +147.9% | 578,195 | +191.3% | 0.12% | +93.7% |
| Q2 2020 | $9,622,000 | -66.5% | 198,510 | -70.4% | 0.06% | -58.3% |
| Q4 2019 | $28,706,000 | +66658.1% | 671,009 | +41838.1% | 0.15% | – |
| Q2 2019 | $43,000 | -99.6% | 1,600 | -99.6% | 0.00% | -100.0% |
| Q1 2019 | $10,513,000 | -71.1% | 391,528 | -82.6% | 0.05% | -72.9% |
| Q4 2018 | $36,328,000 | -12.8% | 2,246,600 | +11.9% | 0.18% | +2.9% |
| Q3 2018 | $41,665,000 | -47.5% | 2,007,000 | -61.4% | 0.17% | -45.7% |
| Q2 2018 | $79,320,000 | -25.8% | 5,194,501 | +9.2% | 0.32% | -29.1% |
| Q1 2018 | $106,899,000 | +48.2% | 4,757,426 | +98.5% | 0.45% | +43.7% |
| Q4 2017 | $72,147,000 | +56.3% | 2,396,098 | +95.6% | 0.31% | +51.0% |
| Q3 2017 | $46,153,000 | +17.7% | 1,225,200 | -12.9% | 0.21% | -6.4% |
| Q2 2017 | $39,214,000 | -40.9% | 1,406,022 | -27.2% | 0.22% | -40.5% |
| Q1 2017 | $66,395,000 | +87.9% | 1,931,200 | +57.6% | 0.37% | +49.8% |
| Q4 2016 | $35,329,000 | -49.3% | 1,225,000 | -44.1% | 0.25% | -49.6% |
| Q3 2016 | $69,721,000 | +79.0% | 2,191,800 | +82.7% | 0.49% | +84.9% |
| Q2 2016 | $38,942,000 | -47.9% | 1,199,700 | -55.1% | 0.26% | -53.8% |
| Q1 2016 | $74,729,000 | +590.0% | 2,672,700 | +779.8% | 0.57% | +544.9% |
| Q4 2015 | $10,830,000 | -83.7% | 303,800 | -84.9% | 0.09% | -83.0% |
| Q3 2015 | $66,537,000 | +17.9% | 2,012,000 | +49.3% | 0.52% | +33.5% |
| Q2 2015 | $56,423,000 | -23.0% | 1,347,256 | -40.1% | 0.39% | -21.6% |
| Q1 2015 | $73,240,000 | +126.5% | 2,247,300 | +120.6% | 0.50% | +119.8% |
| Q4 2014 | $32,341,000 | +41.2% | 1,018,600 | +10.1% | 0.23% | +32.0% |
| Q3 2014 | $22,903,000 | -6.3% | 925,000 | -14.5% | 0.17% | +9.6% |
| Q2 2014 | $24,442,000 | – | 1,082,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |